The globally leading Pharmaceutical Company called Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) is now under the scanner of Faruqi and Faruqi. As a Questcor investor alert, Faruqi and Faruqi, LLP has announced investigation of QCOR (Questcor Pharmaceuticals, Inc.) over the sale of the company to Mallinckrodt plc. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) shares after opening at $82.00 moved to $85.69 on last trade day and at the end of the day closed at $85.16. Company price to sales ratio in past twelve months was calculated as 6.46 and price to cash ratio as 21.06. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) showed a positive weekly performance of 23.19%.
Celgene (NASDAQ:CELG) shares are notably higher Wednesday on what appears to be an investor relief rally over the patent life of Revlimid, the company’s biggest selling cancer drug. Documents pertaining to an upcoming pre-trial “Markman” hearing were made public which appear to favor Celgene over Natco, the generic drug maker challenging certain Revlimid patents. Celgene Corporation (NASDAQ:CELG) shares advanced 6.58% in last trading session and ended the day on $147.32. CELG return on equity ratio is recorded as 25.80% and its return on assets is 11.50%. Celgene Corporation (NASDAQ:CELG) yearly performance is 21.94%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s leading product Iclusig has a competitive advantage over other to treat chronic blood cancer. The product is well accepted across the U.S. and Europe, and reported an increase in revenue since launch. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved up 3.96% in last trading session and was closed at $7.59, while trading in range of $7.27 – $7.61. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is 11.29%.
Gilead Sciences, Inc. (NASDAQ:GILD) announced results from an open-label clinical trial (Study GS-US-334-0109) evaluating once-daily Sovaldi(R) (sofosbuvir) 400 mg tablets for the retreatment of chronic hepatitis C virus (HCV) infection among patients who failed prior therapy. These data will be presented in two oral sessions at the 49th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress 2014) in London. Gilead Sciences, Inc. (NASDAQ:GILD) weekly performance is -4.48%. On last trading day company shares ended up $70.65. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is -9.81%. Analysts mean target price for the company is $98.42.